DURECT Corp. Reports Positive Results from DUR-928 Multi-Dose Ph
May 18, 2015 at 08:32 AM EDT
DURECT Corporation (Nasdaq: DRRX) today announced that it has obtained positive results from a multi-dose Phase 1 clinical trial with an ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.